Fasentin (CAS 392721-37-8)

Fasentin is a novel glucose uptake (GluT1) inhibitor. Evasion of death receptor ligand-induced apoptosis is an important contributor to cancer development and progression. Therefore, compounds that restore sensitivity to death receptor stimuli would be important tools to better understand this biological pathway and provide potential leads for therapeutic adjuncts. Sensitizes cells to FAS-induced cell death. Fasentin selectively sensitized to death ligands, but did not decrease FLIP expression. It alters gene expression associated with nutrient and glucose deprivation. Fasentin interacted with a unique site in the intracellular channel of the glucose transport protein GLUT1. It highlights a new mechanism to sensitize cells to death ligands. Dipyridamole (sc-200717), which is a weak GluT inhibitor which partially inhibits glucose uptake ane sensitize cells to FAS. Two glucose uptake inhibitor, phloretin cytochalasin B, have been reported to be highly toxic and not sensitize cells to FAS.